Aspiriant, LLC Q1 2023 vs. Q2 2023 13F Holdings Comparison
Ava Hoppe | 28 July, 2023
In today's blog post, we will be discussing the changes in holdings of Aspiriant, LLC's Q1 2023 and Q2 2023 filings. We will explore the key highlights and analyze the shifts in their portfolio.
As a quick background, 13F filings are reports required by the Securities and Exchange Commission (SEC) that provide information on the holdings of institutional investment managers with assets under management greater than $100 million. These filings offer valuable insights into the investments made by these firms and help investors track their activities.
Now, let's dive into the data and examine the significant changes in Aspiriant, LLC's portfolio.
ACWV - iShares Inc:
- Q1 2023 (SHARES): 2,839,032
- Q2 2023 (SHARES): 2,801,934
- Q1 2023 VALUE ($000): 274,676
- Q2 2023 VALUE ($000): 274,743
- Chg %: 0
VTEB - Vanguard Mun Bd Fds:
- Q1 2023 (SHARES): 4,016,961
- Q2 2023 (SHARES): 3,945,736
- Q1 2023 VALUE ($000): 203,499
- Q2 2023 VALUE ($000): 198,154
- Chg %: -2.6
IUSV - iShares TR:
- Q1 2023 (SHARES): 2,304,801
- Q2 2023 (SHARES): 2,282,871
- Q1 2023 VALUE ($000): 170,048
- Q2 2023 VALUE ($000): 178,657
- Chg %: 5.1
VIG - Vanguard Specialized Funds:
- Q1 2023 (SHARES): 955,883
- Q2 2023 (SHARES): 951,102
- Q1 2023 VALUE ($000): 147,215
- Q2 2023 VALUE ($000): 154,486
- Chg %: 4.9
VBR - Vanguard Index Fds:
- Q1 2023 (SHARES): 723,560
- Q2 2023 (SHARES): 723,574
- Q1 2023 VALUE ($000): 114,871
- Q2 2023 VALUE ($000): 119,679
- Chg %: 4.2
EFV - iShares TR:
- Q1 2023 (SHARES): 1,292,616
- Q2 2023 (SHARES): 1,280,269
- Q1 2023 VALUE ($000): 62,730
- Q2 2023 VALUE ($000): 62,656
- Chg %: -0.1
VOO - Vanguard Index Fds:
- Q1 2023 (SHARES): 151,437
- Q2 2023 (SHARES): 149,837
- Q1 2023 VALUE ($000): 56,949
- Q2 2023 VALUE ($000): 61,023
- Chg %: 7.2
IEMG - iShares Inc:
- Q1 2023 (SHARES): 1,111,221
- Q2 2023 (SHARES): 1,116,985
- Q1 2023 VALUE ($000): 54,216
- Q2 2023 VALUE ($000): 55,056
- Chg %: 1.5
AAPL - Apple Inc:
- Q1 2023 (SHARES): 285,728
- Q2 2023 (SHARES): 275,658
- Q1 2023 VALUE ($000): 47,116
- Q2 2023 VALUE ($000): 53,469
- Chg %: 13.5
IVV - iShares TR:
- Q1 2023 (SHARES): 106,545
- Q2 2023 (SHARES): 117,863
- Q1 2023 VALUE ($000): 43,798
- Q2 2023 VALUE ($000): 52,532
- Chg %: 19.9
These are just a few of the holdings that have experienced changes in Aspiriant, LLC's portfolio. It's important to note that these changes could be influenced by various factors such as market conditions, investment strategies, and market outlook. Therefore, investors should closely study the full 13F filing for a comprehensive understanding of Aspiriant, LLC's investment decisions.
Please remember that this article is for informational purposes only and should not be considered as financial advice. It's always recommended to consult with a qualified financial advisor before making any investment decisions.
In conclusion, the Q1 2023 vs. Q2 2023 13F holdings comparison of Aspiriant, LLC reveals interesting shifts in their investment portfolio. Investors in the financial markets can use this information as a starting point for further analysis and exploration of potential investment opportunities. Stay tuned for more updates and analysis on the ever-evolving world of investments!
Other Posts
- Wintergreen Advisers, LLC Q4 2018 vs Q1 2019: Significant Shifts in Holdings
- Gibraltar Capital Management, Inc. Q2 2023 vs. Q3 2023 13F Holdings Comparison
- Navigating Health's Financial Pulse: Latticework's Fund II Outshines Expectations with a Hearty $345 Million
- The Transformation of Gideon Capital Advisors: A 13F Holdings Comparison between Q1 and Q2 2020
- **Navigating the Investment Waters: Clarus Wealth Advisors' Strategic Shifts from Q4 2023 to Q1 2024**
- Corsair's Acquisition of MJM Holdings: A Strategic Move in the European Commercial Insurance Industry
- Expanding Piñon Midstream's Dark Horse Treating Facility for Sustainable Energy Production
- Hapanowicz & Associates Financial Services, Inc Q4 2022 vs. Q1 2023: A Comprehensive Comparison of 13F Holdings
- Dalal Street, LLC Q3 to Q4 2022: Analyzing Changes in 13F Holdings
- Iron Path Capital-backed VION Biosciences: Revolutionizing the Life Science Sector